O

    Oric Pharmaceuticals Inc (ORIC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.99
    -0.25 (-1.89%)

    Market Cap: $1.37B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(13/26)
    Avg Surprise
    -6.07%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.37
    Range$-0.45 - $-0.32
    13 analysts
    EPS Revisions
    1
    0
    7d
    1
    6
    30d
    EPS Estimate Drift
    90d ago$-0.37+1.1%
    60d ago$-0.37+0.4%
    30d ago$-0.37+0.4%
    7d ago$-0.38-0.3%
    Current$-0.37
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    Dec 31, 2026
    EPS Consensus$-0.42
    Range$-0.58 - $-0.19
    13 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.42---
    Sep 26EST
    		-$-0.37---
    Jun 26
    		$-0.38$-0.36-5.56%Miss+19.1%
    Mar 26
    		$-0.34$-0.32-6.25%Miss+19.0%
    Dec 25
    		$-0.30$-0.37+18.23%Beat+41.2%
    Sep 25
    		$-0.33$-0.40+17.50%Beat+32.7%
    Jun 25
    		$-0.47$-0.44-6.82%Miss-4.4%
    Mar 25
    		$-0.42$-0.50+16.00%Beat-13.5%
    Dec 24
    		$-0.51$-0.51-0.31%Miss-4.1%
    Sep 24
    		$-0.49$-0.47-4.26%Miss-11.4%
    Jun 24
    		$-0.45$-0.41-9.76%Miss+10.0%
    Mar 24
    		$-0.37$-0.43+13.95%Beat+30.2%
    Dec 23
    		$-0.49$-0.49+0.00%Beat+5.8%
    Sep 23
    		$-0.44$-0.46+4.35%Beat+30.2%
    Jun 23
    		$-0.50$-0.57+12.28%Beat+2.0%
    Mar 23
    		$-0.53$-0.54+1.85%Beat+10.2%
    Dec 22
    		$-0.52$-0.54+3.70%Beat+10.3%
    Sep 22
    		$-0.63$-0.55-14.55%Miss-34.0%
    Jun 22
    		$-0.51$-0.60+15.00%Beat+10.5%
    Mar 22
    		$-0.59$-0.57-3.51%Miss-31.1%
    Dec 21
    		$-0.58$-0.57-1.75%Miss+31.0%
    Sep 21
    		$-0.47$-0.58+18.97%Beat+44.0%
    Jun 21
    		$-0.57$-0.49-16.33%Miss-11.8%
    Mar 21
    		$-0.45$-0.48+6.25%Beat-7.1%
    Dec 20
    		$-0.84$-0.46-82.61%Miss-950.0%
    Sep 20
    		$-0.84$-0.39-115.38%Miss-
    Jun 20
    		$-0.51$-0.40-27.50%Miss-
    Mar 20
    		$-0.42$-0.46+8.70%Beat-
    Dec 19
    		$-0.08$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-9.62EV/EBITDA0.13x
    Price/FCF-12.50xFCF Yield-8.00%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-39.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio13.19xQuick Ratio13.19x
    Trading Statistics
    Beta0.97Avg Volume1.39M
    52-Week High$14.9352-Week Low$7.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.78
    SMA 20$13.64
    SMA 50$11.88
    SMA 200$10.65
    EMA 10$13.54
    EMA 20$13.28
    EMA 50$12.14
    EMA 200$10.77

    MACD

    Line: 0.49Signal: 0.69Hist: -0.20

    ADX

    ADX: 37.0+DI: 20.6-DI: 19.0

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down20.0
    PSAR$14.68

    Bollinger Bands

    Upper Band$14.48
    Lower Band$12.79
    %B Position1242%(Upper)
    Band Width0.12

    RSI (14-Day)

    Neutral
    50.0

    Momentum Oscillators

    Stoch %K21.2
    Stoch %D36.3
    Williams %R-84.1
    ROC (10d)-2.9%
    Momentum-0.39
    CCI (20d)-129.2
    MFI (14d)43.0

    Volatility Measures

    ATR (14d)$0.75(5.8%)
    StdDev (20d)0.42
    Hist Vol108.3%(High)

    Volume Flow

    VWAP$12.95
    OBV473.5K
    AD Line-5.9M
    CMF (20d)0.182

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.9x
    VWMA (20d)$13.60

    Pivot Points

    R3$14.44
    R2$14.18
    R1$13.71
    Pivot Point$13.46
    S1$12.98
    S2$12.73
    S3$12.26

    Advanced Oscillators

    TSI17.16
    Ultimate Osc41.5
    KST204.41

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.07M$0$0$0$1.54M$0
    Cost of Revenue$0$0$320,000$0$0$0$304,000$0$0$0$263,000$0
    Gross Profit$0$0$-320,000$0$0$0$-304,000$0$0$0$-263,000$0
    Operating Expenses$45.30M$39.62M$34.55M$36.67M$39.06M$32.72M$39.57M$38.32M$36.02M$28.99M$31.43M$28.68M
    R&D$36.30M$31.44M$25.86M$28.77M$30.55M$24.64M$31.97M$31.20M$28.94M$21.96M$24.48M$22.39M
    SG&A$9.00M$8.18M$8.70M$7.90M$8.52M$8.08M$7.60M$7.12M$7.08M$7.03M$6.95M$6.29M
    Operating Income$-45,296,000$-39,619,000$-34,551,000$-36,671,000$-39,064,000$-32,718,000$-39,570,000$-38,318,000$-36,017,000$-28,990,000$-31,428,000$-28,682,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-41,492,000$-35,767,000$-30,505,000$-32,587,000$-36,355,000$-30,021,000$-36,307,000$-34,566,000$-31,963,000$-25,011,000$-28,330,000$-25,478,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-41,492,000$-35,767,000$-30,505,000$-32,587,000$-36,355,000$-30,021,000$-36,307,000$-34,566,000$-31,963,000$-25,011,000$-28,330,000$-25,478,000
    EBITDA$-44,741,000$-39,187,000$-34,471,000$-36,970,000$-39,345,000$-33,298,000$-40,900,000$-39,994,000$-38,041,000$-30,956,000$-33,288,000$-30,347,000
    EBIT$-45,296,000$-39,619,000$-34,551,000$-36,671,000$-39,064,000$-32,718,000$-39,570,000$-38,318,000$-36,017,000$-28,990,000$-31,428,000$-28,682,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ORIC

    News

    Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC

    Blue Owl Capital Holdings LP has invested $4.33 million in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), acquiring 400,000 shares, which represents 0.39% of ORIC and 0.7% of Blue Owl's portfolio. Institutional ownership of Oric Pharmaceuticals is high at 95.05%, with major firms like BlackRock and Vanguard increasing their stakes. Despite a recent stock dip and an EPS miss, analysts generally maintain a "Moderate Buy" rating with an average price target of $19.45.

    MarketBeat•8/21/26•
    Neutral

    HC Wainwright Issues Pessimistic Outlook for ORIC Earnings

    HC Wainwright has revised down its earnings per share forecasts for Oric Pharmaceuticals (NASDAQ:ORIC) for Q3 2026 and FY2026, projecting larger losses. Despite the more pessimistic outlook, HC Wainwright maintained a "Buy" rating and a $27 price target on the stock. Oric Pharmaceuticals recently missed its Q2 earnings consensus, reporting a loss of $0.38 per share against an estimate of $0.36.

    MarketBeat•8/12/26•
    Somewhat-Bearish

    Understanding Momentum Shifts in (ORIC)

    This article provides an analysis of Oric Pharmaceuticals Inc. (NASDAQ: ORIC), focusing on momentum shifts and potential trading strategies based on AI models. It highlights strong near and mid-term sentiment, identifies compelling upside potential due to the absence of resistance levels, and offers specific position, momentum breakout, and risk hedging trading strategies. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.

    Stock Traders Daily•8/12/26•
    Somewhat-Bullish

    ORIC PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $27 FROM $25

    H.C. Wainwright has raised its target price for ORIC Pharmaceuticals, Inc. from $25 to $27. This adjustment suggests a positive outlook from the analytical firm regarding the company's future performance. The news was reported by Reuters.

    Webull•8/12/26•
    Bullish

    ORIC Pharmaceuticals, Inc. (ORIC) options chain

    This article provides the options chain for ORIC Pharmaceuticals, Inc. (ORIC), including call and put options with various strike prices and expiration dates. It details last trade dates, prices, bids, asks, volume, open interest, and implied volatility for contracts expiring on February 19, 2027. The current stock price of ORIC is reported as $13.96, up 1.68%.

    Yahoo Finance Australia•8/11/26•
    Neutral

    Frequently Asked Questions About ORIC

    Does ORIC pay dividends?
    Oric Pharmaceuticals Inc (ORIC) does not currently pay a regular dividend.
    What is ORIC's market cap?
    Oric Pharmaceuticals Inc (ORIC) has a market capitalization of $1.37B with a current stock price of $12.99.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In